Navigation Links
Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
Date:10/21/2010

and ribavirin.(7,8) Romark is preparing to initiate Phase III clinical trials of nitazoxanide plus peginterferon for treatment of CHC.

About Hepatitis CHCV is a major cause of chronic liver disease, including cirrhosis and liver cancer. According to the World Health Organization (WHO), approximately 170 million people worldwide are chronic HCV carriers (3% of the world's population), including about 10 million Europeans, 3.9 million Americans and 2 million Japanese. 35,000 new infections occur in the United States alone each year. The substantial unmet medical need is underscored by the fact that each year 8,000 to 10,000 deaths and 1,000 liver transplants in the United States are due to HCV.

Currently, there is no vaccine against HCV available, and the infection can only be treated with a combination of interferon and ribavirin – a long-term therapy with limited efficacy and substantial side effects. It also gives rise to high treatment costs for patients. In 2002, worldwide sales of HCV drugs totaled around EUR 2.8bn, and demand has since grown significantly. The market has been seen to expand to about EUR 3.5bn by 2006.

About Romark LaboratoriesRomark Laboratories, L.C. (www.romark.com) is a privately owned biopharmaceutical company committed to the discovery and development of innovative new small molecules for treating infectious diseases and cancers.

The Company is developing a new class of broad-spectrum antiviral drugs called the thiazolides. The first thiazolide, nitazoxanide, is in late-stage clinical development as a treatment of chronic hepatitis C and influenza. Other new thiazolides are expected to enter clinical development in 2011.

Romark markets Alinia® (nitazoxanide) tablets, 500 mg and Alinia® (nitazoxanide) for Oral Suspension, 100 mg/5 mL in the United States.

This communication expressly or implicitly contains certain forward-looki
'/>"/>

SOURCE Intercell AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intercell AG Appoints Staph Leavenworth Bakali as Chief Business Officer
2. Intercell Acquires Antibody Technology Platform to Further Exploit Its Capabilities to Combat Infectious Diseases
3. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
4. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
5. Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
6. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
7. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
8. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
9. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
10. NeuroFocus and New Scientist Magazine Apply Neuromarketing to Select Cover Design
11. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014  STAAR Surgical Company (NASDAQ: STAA ) ... delivery systems for the eye, today announced that management will ... New York Palace Hotel on Wednesday, September 3 at 7:15 ... President and CEO will offer a general overview of the ... be joined by Steve Brown , CFO, and ...
(Date:8/28/2014)... , Aug. 28, 2014 Synthetic Biologics, ... anti-infective biologic and drug candidates targeting specific pathogens ... Diosynth Biotechnologies UK Limited (Fujifilm), announced today confirmation ... cGMP manufacturing of SYN-004, Synthetic Biologics, proprietary oral ... difficile ( C. difficile ) infections. ...
(Date:8/28/2014)... -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ... trials evaluating the use of collagenase clostridium histolyticum (CCH) for ... with a palpable cord will be presented at the upcoming ... Surgery of the Hand (ASSH) being held in ... (CCH) is a biologic approved in the U.S., EU, ...
Breaking Medicine Technology:STAAR Surgical To Present At The Baird 2014 Health Care Conference 2Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 2Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 3Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 4Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 5Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 2Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 3Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 4Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 5Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 6
... Medical Systems Ltd. (NASDAQ: DHRM) ("Dehaier" or ... assembly, marketing and sale of medical devices and ... plans to release its financial results for the ... 31, 2011 on Monday, March 19, 2012, after the stock ...
... Timothy C. Tyson, Aptuit Chairman, announced that effective immediately, ... Operating Officer of Aptuit LLC. Following the recent sale ... has been promoted from his previous position at Aptuit ... Needleman is responsible for all day-to-day operations of the ...
Cached Medicine Technology:Dehaier Medical Systems Schedules 2011 Fourth Quarter and Full Year Financial Results and Conference Call 2Dehaier Medical Systems Schedules 2011 Fourth Quarter and Full Year Financial Results and Conference Call 3Aptuit LLC Names Stuart E. Needleman as President and Chief Operating Officer 2
(Date:8/28/2014)... (PRWEB) August 28, 2014 Edvance360 ... the top ten tools for online teaching, as well ... for Best Course or Learning Management System, announced that ... Academy, Typewell, Dialysis Treatment Center of America, Metis Leadership ... and HMG Plus, to the user community. , ...
(Date:8/28/2014)... 2014 Every year, cataracts affect over 22 ... the leading cause of blindness in the world. Characterized by ... the iris, cataracts are estimated to affect an additional 30 ... aging population. Cataracts are just one of the many conditions ... Tracy of Carlsbad Eye Care screens patients for a number ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Labor Day ... the beach and those last glorious glimpses of summer. ... patients are planning on spending their long weekend recovering ... Sadati, a board certified facial plastic and reconstructive surgeon ... patients have taken advantage of their holiday weekends to ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Atlantic Information ... of the latest addition to its Management Insight Series, ... a Major Patient Privacy/Security Risk . The new report ... manage the risks associated with portable electronic devices, and ... federal requirements. , With expert advice on how to ...
(Date:8/28/2014)... 2014 In the healthcare industry, there ... struggle with: How can the overall quality of patient ... of the healthcare industry tackles this question, and has ... job satisfaction and the quality of patient care. ... in “ Organizational Factors related to Improving Quality of ...
Breaking Medicine News(10 mins):Health News:Edvance360 Continues to Experience Growth in Corporate, K-12, Health, and Non-Profit Sectors 2Health News:Cataract Awareness Month an Opportunity to Focus on Vision Care and Ocular Health 2Health News:Newport Beach Facial Plastic Surgeon, Dr. Kevin Sadati Announces a Patient Trend of Scheduling Cosmetic Surgery Procedures over Long Holiday Weekends 2Health News:Newport Beach Facial Plastic Surgeon, Dr. Kevin Sadati Announces a Patient Trend of Scheduling Cosmetic Surgery Procedures over Long Holiday Weekends 3Health News:Newport Beach Facial Plastic Surgeon, Dr. Kevin Sadati Announces a Patient Trend of Scheduling Cosmetic Surgery Procedures over Long Holiday Weekends 4Health News:New Report Offers Best Practices for Avoiding the Patient Privacy/Security Risks Posed by Mobile Devices 2Health News:New Healthcare Study Explores Strategies for Improving Patient Care 2Health News:New Healthcare Study Explores Strategies for Improving Patient Care 3Health News:New Healthcare Study Explores Strategies for Improving Patient Care 4
... July 7 HealthSouth,Corporation (NYSE: HLS ) ... to acquire a 30-bed inpatient rehabilitation unit at ... is currently owned by Columbia,Medical Center of Arlington ... operations will relocate to HealthSouth Rehabilitation,Hospital of Arlington., ...
... recycling benefits our planet; and now new research suggests ... cancer. Scientists at Stanford University have identified a molecule ... cells. The research, published by Cell Press in the ... , may drive treatment strategies for cancer in an ...
... and geographic boundaries are some of the challenges that ... for a possible influenza pandemic, according to a new ... who are leading planning efforts for an influenza outbreak ... defined by political lines," said George Avery, an assistant ...
... Pa., July 7 Digestive Care, Inc. (DCI),announced today ... New Drug,Application ("NDA") for PANCRECARB(R) (pancrelipase), used in the ... and Drug,Administration ("FDA"). The FDA has granted the product ... used to treat EPI for over,a decade and we ...
... Satisfaction Rate 94% - 100%, ARLINGTON HEIGHTS, ... after an elective mastectomy are satisfied with,their decision, ... do it,again, reports a study in July,s Plastic ... American Society of Plastic Surgeons,(ASPS). In addition, breast ...
... Ill. Women who have breast reconstruction after an ... complication rates and 98 percent would do it again, ... Surgery , the official medical journal of the American ... reconstruction after preventive mastectomy was as safe as or ...
Cached Medicine News:Health News:HealthSouth To Acquire Rehabilitation Unit at Medical Center of Arlington 2Health News:HealthSouth To Acquire Rehabilitation Unit at Medical Center of Arlington 3Health News:Can recycling be used to treat cancer? 2Health News:Political borders, health-care issues complicate pandemic planning 2Health News:Political borders, health-care issues complicate pandemic planning 3Health News:Digestive Care, Inc. Announces the Filing of the First Module of NDA Submission for PANCRECARB(R) (pancrelipase) 2Health News:98% of Elective Mastectomy Patients Would Have Reconstruction Again, Says ASPS Study 2Health News:98 percent of elective mastectomy patients would have reconstruction again, says ASPS study 2
... is ideal for all liquid handling applications ... operating buttons, and various dispensing techniques such ... make this a lab favorite. It intuitively ... pipette without any adverse effects on the ...
Single channel module for Finnpipette Biocontrol - Universal handle sold separately...
... the ease and comfort you've come to expect ... in clinical trials agreed that the BD Lancet ... settings allow you to choose the best lancet ... lancets, the device also helps eliminate the "vibrations" ...
... StaRRsed-III is a system that measures ... samples. This rate may be relevant ... The sedimentation rate is measured in ... typically used in high-volume settings such ...
Medicine Products: